-transparent.png){kind=logo}
Four patients with myasthenia gravis were under unsatisfactory control while receiving oral pyridostigmine. In each of these patients, the serum levels of this drug were below those observed in patients with myasthenia gravis who are well controlled. The strength of each of these patients improved when the serum pyridostigmine level was increased by intravenous administration of this agent. Furthermore, the rate of disappearance of pyridostigmine from the serum following intravenous administration was the same as that for control subjects and patients under good control. This demonstrates that failure to achieve adequate serum pyridostigmine levels following oral administration is due to malabsorption rather than to increased rates of tissue uptake, degradation, or excretion of the drug.
S L Cohan, and
K L Dretchen, and
A Neal
February 1977,
Clinical pharmacology and therapeutics,
S L Cohan, and
K L Dretchen, and
A Neal
January 1977,
European neurology,
S L Cohan, and
K L Dretchen, and
A Neal
October 1987,
Archives of neurology,
S L Cohan, and
K L Dretchen, and
A Neal
November 1977,
Neurology,
S L Cohan, and
K L Dretchen, and
A Neal
August 1955,
Revista clinica espanola,
S L Cohan, and
K L Dretchen, and
A Neal
May 1985,
Clinical pharmacology and therapeutics,
S L Cohan, and
K L Dretchen, and
A Neal
February 1981,
Neurology,
S L Cohan, and
K L Dretchen, and
A Neal
July 1956,
Canadian Medical Association journal,
S L Cohan, and
K L Dretchen, and
A Neal
October 1983,
Journal of neurology, neurosurgery, and psychiatry,
S L Cohan, and
K L Dretchen, and
A Neal
May 1953,
Deutsche medizinische Wochenschrift (1946),
